Anivive, a revolutionary pet pharmaceutical company, has appointed Kevin McCarthy to its Board of Directors for his expertise in government and Valley Fever advocacy. Anivive's groundbreaking vaccine is set to combat Valley Fever in both pets and humans, showing efficacy in over a dozen studies. With a $33 million contract for manufacturing and clinical trials, Anivive aims to launch the vaccine for canines by 2025.
Revolutionizing Veterinary Healthcare
Anivive plans to extend its AI-driven treatments to help endangered zoo species, marking a significant leap in veterinary health innovation.